Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$43.53-1.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · SUPN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
The filing describes a new employment agreement for the current CEO and President, contingent on a merger.
Other Events. As previously announced, on August 3, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) and Indivior Pharmaceuticals Inc. (“Indivior”) are hosting a conference call and webcast at 8:30 a.m., Eastern Time, to present information regarding the proposed merger of the Company and Indivior. The Company intends to display the slides filed as Exhibit 99.1 hereto during the presentation. Important Additional Information and Where to Find It In connection with the proposed transaction…
Other Events. On August 3, 2026, the Company and Indivior issued a joint press release announcing the execution of the Merger Agreement. A copy of the joint press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference. The Company and Indivior will host a joint conference call and webcast on Monday, August 3, 2026 at 8:30 a.m. EDT. A replay of the webcast will be available following the event. An investor presentation, which will be referenced during the webcast, will…
Results of Operations and Financial Condition On August 3, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus and Invidior Pharmaceuticals, Inc. ("Invidior") have entered into a definitive agreement to combine in an all-stock merger of equals…
Entry into a Material Definitive Agreement. Agreement and Plan of Merger On August 1, 2026 (the “Signing Date”), Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Supernus”), entered into a Merger Agreement (the “Merger Agreement”), by and among the Company, Indivior Pharmaceuticals Inc., a Delaware corporation (“Indivior”), and Artemis Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Indivior (“Merger Sub”). Pursuant to the Merger Agreement, a…
Other Events. On August 3, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) published a post relating to the proposed merger of equals of the Company and Indivior Pharmaceuticals Inc. (“Indivior”) on the Company’s LinkedIn account. In addition, on August 3, 2026, the Company distributed to its employees communications relating to the proposed merger, consisting of an email to Company employees from Jack A. Khattar, the Company’s President and Chief Executive Officer, and a presentation us…
Results of Operations and Financial Condition. On July 22, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it will report its business results for the second quarter of 2026 after the market closes on Tuesday, August 4, 2026. The Company will host a conference call and webcast on Tuesday, August 4, 2026 at 4:30 p.m. E.T. to discuss its second quarter 2026 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorpo…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On May 17, 2026 (the “Notice Date”), pursuant to the Contingent Value Right Agreement (the “CVR Agreement”) entered into as of July 30, 2025, by and between Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Equiniti Trust Company, LLC, a New York limited liability trust company, as Rights Agent, the Company notified the Rights Agent that Milestone 1, as d…
Results of Operations and Financial Condition. On May 5, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the first quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, May 5, 2026, to present the business and financial results. A live…
Results of Operations and Financial Condition. On April 22, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it will report its business results for the first quarter of 2026 after the market closes on Tuesday, May 5, 2026. The Company will host a conference call and webcast on Tuesday, May 5, 2026 at 4:30 p.m. E.T. to discuss its first quarter 2026 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated h…
Entry Into a Material Definitive Agreement. Entry into Asset Purchase Agreement On April 1, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Agreement”), together with related ancillary transaction documents, with Navitor Pharmaceuticals, Inc., a Delaware corporation (“Navitor”), Navitor Pharmaceuticals, LLC, a Delaware limited liability company (“Navitor Parent,” and, together with Navitor, the “Sellers”). The Agreement is entered into as co…
Completion of Acquisition or Disposition of Asset. The information set forth in
Compensation modifications and equity grants for executive officers.
Results of Operations and Financial Condition. On February 24, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the fourth quarter ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, February 24, 2026, to present the business and financial…
Results of Operations and Financial Condition. On February 12, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the fourth quarter of 2025 after the market closes on Tuesday, February 24, 2026. The Company will host a conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. E.T. to discuss its fourth quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 heret…
Entry into a Material Definitive Agreement. On January 22, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) entered into a First Amendment (the “Amendment”) to the Agreement and Plan of Merger dated September 12, 2018 (the “Merger Agreement”), with Reich Consulting Group, Inc. as the Securityholder Representative. The Amendment relates to the timing and payment of certain milestones under the Merger Agreement. The foregoing description is qualified in its entirety by reference to the full…
Results of Operations and Financial Condition. On November 4, 2025, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the third quarter September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, November 4, 2025, to present the business and financial results.…
Results of Operations and Financial Condition. On October 21, 2025, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the third quarter of 2025 after the market closes on Tuesday, November 4, 2025. The Company will host a conference call and webcast on Tuesday, November 4, 2025 at 4:30 p.m. E.T. to discuss its third quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and…
Results of Operations and Financial Condition. On August 5, 2025, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the second quarter June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, August 5, 2025, to present the business and financial results. A live…
Chief Technical Operations Officer — Frank Mottola: The filing discloses the internal promotion of Frank Mottola to Chief Technical Operations Officer with a corresponding salary increase, which is a standard succession or advancement event rather than a departure.
Other Events. On July 31, 2025, Supernus issued a press release announcing the successful completion of its acquisition of Sage, including the completion of both the Offer and the Merger. A copy of the press release is filed as Exhibit 99.1 hereto, and the text of such press release is incorporated herein by reference. Forward-Looking Statements This filing includes forward-looking statements. These statements do not convey historical information but relate to predicted or potential future ev…
Completion of Acquisition or Disposition of Assets. Pursuant to the Merger Agreement, on July 2, 2025, Purchaser commenced a tender offer to purchase all of the outstanding shares of common stock of Sage, par value $0.0001 per share (the “ Shares ”), at a price of (i) $8.50 per Share, in cash, less any applicable withholding taxes and without interest (the “ Closing Amount ”), plus (ii) one contingent value right per Share (a “ CVR ”), which represents the right to receive contingent payments…
Entry into a Material Definitive Agreement. As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “ SEC ”) by Supernus Pharmaceuticals, Inc., a Delaware corporation (the “ Supernus ”), on June 16, 2025, Supernus entered into an Agreement and Plan of Merger, dated as of June 13, 2025 (the “ Merger Agreement ”), with Sage Therapeutics, Inc., a Delaware corporation (“ Company ” or “ Sage ”), and Saphire, Inc., a Delaware corporation and…
Results of Operations and Financial Condition. On July 22, 2025, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025. The Company will host a conference call and webcast on Tuesday, August 5, 2025 at 4:30 p.m. E.T. to discuss its second quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is i…
Entry into a Material Definitive Agreement. On June 13, 2025, Supernus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Sage Therapeutics, Inc., a Delaware corporation (“Sage”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Sage and Saphire Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“Purchaser”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, the Co…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.